0001104659-24-058808.txt : 20240508 0001104659-24-058808.hdr.sgml : 20240508 20240508170046 ACCESSION NUMBER: 0001104659-24-058808 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24927280 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K/A 1 tm2413796d1_8ka.htm FORM 8-K/A
false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-14 2024-02-14 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-14 2024-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K/A

(AMENDMENT NO. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 14, 2024

 

ABBVIE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35565   32-0375147
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

 

 

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code) 

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 20, 2024, AbbVie Inc. (“AbbVie”) filed a Form 8-K to announce that the Board of Directors (the “Board”) selected Robert A. Michael to succeed Richard A. Gonzalez as AbbVie’s Chief Executive Officer (CEO), effective July 1, 2024 (the “Effective Date”). Upon the Effective Date, Mr. Michael will become a member of the Board as a Class II director and Mr. Gonzalez will become Executive Chairman of the Board.

 

On May 2, 2024, the Board approved Mr. Michael's new compensation package as CEO, as of the Effective Date, as follows:

 

·Mr. Michael will receive an annual base salary of $1,700,000.

·Mr. Michael will continue to be eligible to participate in AbbVie’s Performance Incentive Plan or any successor annual bonus plan with a target bonus equal to 150% of his base salary, subject to the attainment of one or more pre-established performance targets.

 

Mr. Gonzalez’s new compensation package as Executive Chairman was also approved as follows:

 

·Mr. Gonzalez will receive an annual base salary of $1,500,000.

·Mr. Gonzalez will continue to be eligible to participate in AbbVie’s Performance Incentive Plan or any successor annual bonus plan with a target bonus equal to 140% of his base salary, subject to the attainment of one or more pre-established performance targets.

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

AbbVie held its 2024 Annual Meeting of Stockholders on May 3, 2024. The following is a summary of the matters voted on at that meeting.

 

(1) The stockholders elected AbbVie’s Class III directors with terms expiring in 2027, as follows:

 

Name  For   Against   Abstain   Broker Non-Votes 
Roxanne S. Austin  1,195,661,209   77,171,745   2,198,609   245,929,517 
Richard A. Gonzalez  1,174,460,841   94,950,345   5,620,377   245,929,517 
Susan E. Quaggin  1,264,358,441   8,524,362   2,148,760   245,929,517 
Rebecca B. Roberts  1,223,837,505   48,797,905   2,396,153   245,929,517 
Glenn F. Tilton  1,171,160,370   101,200,449   2,670,744   245,929,517 

 

(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2024, as follows:

 

For   Against   Abstain 
1,492,584,834   25,439,349   2,936,897 

 

(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows:

 

For   Against   Abstain   Broker Non-Votes 
1,169,920,693   96,635,849   8,475,021   245,929,517 

 

 

 

 

(4) The stockholders approved, on an advisory basis, the frequency of the vote to approve the compensation of AbbVie’s named executive officers, as follows:

 

1 Year   2 Years   3 Years   Abstain   Broker Non-Votes 
1,245,324,966   4,703,272   18,046,245   6,957,080   245,929,517 

 

The Board had recommended a vote for holding future say on pay votes on an annual basis. In light of the voting result, AbbVie has determined to hold future say on pay votes on an annual basis until the next advisory vote on the frequency of say on pay votes, which is required to occur no later than AbbVie’s 2030 Annual Meeting of Stockholders.

 

(5) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

 

For   Against   Abstain   Broker Non-Votes 
1,249,248,243   21,439,823   4,343,497   245,929,517 

 

(6) The stockholders did not approve a stockholder proposal to implement simple majority voting, as follows:

 

For   Against   Abstain   Broker Non-Votes 
623,935,599   644,183,358   6,912,606   245,929,517 

 

(7) The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows:

 

For   Against   Abstain   Broker Non-Votes 
341,147,876   920,953,722   12,929,965   245,929,517 

 

(8) The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows:

 

For   Against   Abstain   Broker Non-Votes 
315,426,248   941,651,498   17,953,817   245,929,517 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ABBVIE INC.
       
Date: May 8, 2024 By: /s/ Perry C. Siatis
      Perry C. Siatis
     

Executive Vice President, General Counsel and Secretary

 

 

 

 EX-101.SCH 2 abbv-20240214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 abbv-20240214_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 abbv-20240214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] NEW YORK STOCK EXCHANGE, INC. [Member] NYSE CHICAGO, INC. [Member] Senior Notes 1. 375 Percentdue 2024 [Member] Senior Notes 1. 250 Percentdue 2024 [Member] Senior Notes 0. 750 Percentdue 2027 [Member] Senior Notes 2. 125 Percentdue 2028 [Member] Senior Notes 2. 625 Percentdue 2028 [Member] Senior Notes 2. 125 Percentdue 2029 [Member] Senior Notes 1. 250 Percentdue 2031 [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 abbv-20240214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Feb. 14, 2024
Document Information [Line Items]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Feb. 14, 2024
Entity File Number 001-35565
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Entity Tax Identification Number 32-0375147
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock [Member] | NYSE CHICAGO, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name CHX
Senior Notes 1. 375 Percentdue 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Senior Notes 1. 250 Percentdue 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2024
Trading Symbol ABBV24B
Security Exchange Name NYSE
Senior Notes 0. 750 Percentdue 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Senior Notes 2. 125 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Senior Notes 2. 625 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.625% Senior Notes due 2028
Trading Symbol ABBV28B
Security Exchange Name NYSE
Senior Notes 2. 125 Percentdue 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2029
Trading Symbol ABBV29
Security Exchange Name NYSE
Senior Notes 1. 250 Percentdue 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 10 22 1 false 10 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbvie.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:Security12bTitle, dei:TradingSymbol - tm2413796d1_8ka.htm 22, 23 abbv-20240214.xsd abbv-20240214_def.xml abbv-20240214_lab.xml abbv-20240214_pre.xml tm2413796d1_8ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2413796d1_8ka.htm": { "nsprefix": "abbv", "nsuri": "http://abbvie.com/20240214", "dts": { "schema": { "local": [ "abbv-20240214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] }, "definitionLink": { "local": [ "abbv-20240214_def.xml" ] }, "labelLink": { "local": [ "abbv-20240214_lab.xml" ] }, "presentationLink": { "local": [ "abbv-20240214_pre.xml" ] }, "inline": { "local": [ "tm2413796d1_8ka.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 2, "axisCustom": 0, "memberStandard": 3, "memberCustom": 7, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 10, "entityCount": 1, "segmentCount": 10, "elementCount": 75, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 46 }, "report": { "R1": { "role": "http://abbvie.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413796d1_8ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413796d1_8ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://abbvie.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "abbv_SeniorNotes0.750Percentdue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes0.750Percentdue2027Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 0. 750 Percentdue 2027 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes1.250Percentdue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes1.250Percentdue2024Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 1. 250 Percentdue 2024 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes1.250Percentdue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes1.250Percentdue2031Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 1. 250 Percentdue 2031 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes1.375Percentdue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes1.375Percentdue2024Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 1. 375 Percentdue 2024 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes2.125Percentdue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes2.125Percentdue2028Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 2. 125 Percentdue 2028 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes2.125Percentdue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes2.125Percentdue2029Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 2. 125 Percentdue 2029 [Member]" } } }, "auth_ref": [] }, "abbv_SeniorNotes2.625Percentdue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://abbvie.com/20240214", "localname": "SeniorNotes2.625Percentdue2028Member", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Senior Notes 2. 625 Percentdue 2028 [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XCHI", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XNYS", "presentation": [ "http://abbvie.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-058808-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-058808-xbrl.zip M4$L#!!0 ( !:(J%AC?<_5_P, &83 1 86)B=BTR,#(T,#(Q-"YX MLDD94K:3&AS;5XZLKT0-;9$)#F0 M^^M/\J\ QB[F+C?X25Y]W^Y^TFJEP;ME'*%'X((P.C0\-T)#QK]>CTN^=E'/AV?9BL; H M>\0+QN^%%;!X-X<3B64B2F^=92?_=J-?$A&4Y"/\OKQ_#O^^O3ZZ^'Z_E/&???\F_OCAZ?YA['Y_^#GY><)[IS&[O?R8A1R( MX YBC-1F4#$TM+YE:SI %/J)"8!FOX4):$57#/SB;7H&0K]'4&)04TA V< M@,":L4=;32B\VRV B3!G&,]+\!0+/W6:3ZR!!9=5H#)N@DSY- >Q%9I-K1%" MR3<(:ZNFIFT]K3FNV>F:7:=@8M]_+$GZAX"N98U\U7&=5^I$1A #E>>,QV

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tm2413796d1_8ka_htm.xml IDEA: XBRL DOCUMENT 0001551152 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-14 2024-02-14 iso4217:USD shares iso4217:USD shares false 0001551152 Common Stock, $0.01 Par Value ABBV 8-K/A 2024-02-14 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value ABBV NYSE CHX 1.375% Senior Notes due 2024 ABBV24 NYSE 1.250% Senior Notes due 2024 ABBV24B NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 2.625% Senior Notes due 2028 ABBV28B NYSE 2.125% Senior Notes due 2029 ABBV29 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false